This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q66045806
rdf:type
wikibase:Item
schema:description
ensayu clínicu клінічне випробування klinisch onderzoek clinical trial
rdfs:label
Atezolizumab Immunotherapy in Patients With Advanced NSCLC Atezolizumab Immunotherapy in Patients With Advanced NSCLC
skos:prefLabel
Atezolizumab Immunotherapy in Patients With Advanced NSCLC Atezolizumab Immunotherapy in Patients With Advanced NSCLC
schema:name
Atezolizumab Immunotherapy in Patients With Advanced NSCLC Atezolizumab Immunotherapy in Patients With Advanced NSCLC
p:P1476
wds:Q66045806-CE4ABD97-09B4-48B2-9A66-8850A1D7C918
wdt:P1476
Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.
p:P582
wds:Q66045806-7C1A6759-1103-4755-A519-736591F05978
wdt:P582
2020-03-01T00:00:00Z
p:P31
wds:Q66045806-AA1EEFEA-0A22-4A6D-8326-B9D4549BBD5A
wdt:P31
wd:Q30612
p:P580
wds:Q66045806-B98163E1-6ABD-4574-AA76-F1F44EE34C71
wdt:P580
2017-11-01T00:00:00Z
p:P17
wds:Q66045806-63A2E230-9FB0-41DD-AA11-E463526FB809
wdt:P17
wd:Q30
p:P6153
wds:Q66045806-AED5DAA6-F403-4B02-91C7-1909EB6C9495 wds:Q66045806-645B8E9D-9440-4220-8713-7CE908CB5317 wds:Q66045806-FFC61B64-179F-4451-A7F3-2FCEA895F65B wds:Q66045806-94B3CD02-D9C3-4006-ACCF-0713619A2963 wds:Q66045806-9C12F802-21C3-40CD-9E89-B38CB758E469 wds:Q66045806-9F21977F-07AC-46F1-A253-16866B6EB445
wdt:P6153
wd:Q1159198 wd:Q681025 wd:Q1130172 wd:Q7972509 wd:Q131252 wd:Q7401561
p:P4844
wds:Q66045806-2D8433F0-451C-4E59-8791-4E1BBD1F6F2B
wdt:P4844
wd:Q50349184
p:P2899
wds:Q66045806-ED74898F-7BAE-459A-A29E-2F4B044CD32E
wdt:P2899
18
p:P1132
wds:Q66045806-663B3F6F-1020-4F37-94C4-183C7E4DBFE2
wdt:P1132
63
p:P4135
wds:Q66045806-EA3DBC2D-6B91-43AF-BAFC-ABFAB0B10E5B
wdt:P4135
99
p:P8363
wds:Q66045806-401F9220-E171-45F5-BB64-D69793724BD8
wdt:P8363
wd:Q78089383
p:P3098
wds:Q66045806-E19DE633-6BF6-467A-A17B-2E7033060C97
wdt:P3098
NCT03102242
p:P6099
wds:Q66045806-960A6CE0-4B59-4560-AC1C-09C9A943CD58
wdt:P6099
wd:Q42824440